Biotech Values

[DewDiligence]

Re NSTK:

>> I sold some DNDN bought some NSTK <<

Be careful. I find NSTK’s CEO to be even more of a liability than CTIC’s. He is introduced at conference calls and in press releases as “Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer.” Perhaps I’m overreacting, but wouldn’t it be sufficient to leave it at ‘Dr. Stephen Quay, CEO’?

I also don’t care for NSTK’s recent appointment as an “independent” director of someone who pumped NSTK incessantly on the Yahoo message board for years:

http://finance.messages.yahoo.com/bbs?.mm=FN&board=7077075&tid=nstk&sid=7077075&acti...

PYY may turn out to be a good drug, but that’s a long way off. Because the PYY-related IP is scattered and somewhat deficient, many companies may end up splitting the pie if the drug works. In particular, on oral administration of PYY might seriously reduce the competitiveness of NSTK’s nasal formulation.

I also don’t think much of NSTK’s apomorphine program. JMHO, FWIW